Psychiatry MMC

by Carrolee Barlow, MD, PhD; and Steven D. Targum, MD

Psychiatry 2007;4(5):18-20 (more…)

by Leslie Citrome, MD, MPH (more…)

by Randon S. Welton, MD (more…)

(more…)

by Geetha Jayaram, MD, MBA

AUTHOR AFFILIATION: Dr. Jayaram is the Associate Professor of Psychiatry, Johns Hopkins University, Department of Psychiatry, Baltimore, Maryland. (more…)

by Jennifer L. Shoenfelt, MD; and Christina G. Weston, MD; Series Editor: Paulette Marie Gillig, MD, PhD

Editor’s Note: All cases presented in the series “Psychotherapy Rounds” are composites constructed to illustrate teaching and learning points, and are not meant to represent actual persons in treatment.

Author Affiliation: All are from the Department of Psychiatry, Wright State University, Dayton, Ohio.

Abstract
Obsessive compulsive disorder (OCD) in children and adolescents is much the same as in adults with regard to symptoms and basic treatment modalities. There are some distinct considerations to note in the approach to treatment methods. Empirically supported treatments include both medications and cognitive behavioral therapy (CBT). It is important that psychotherapeutic treatment be tailored to the developmental level of the child. In this article, we will present, through case example, samples of varying the psychotherapeutic approach used for both child and adolescent cases of OCD. We will focus on exposure and response prevention techniques.

Key Words: obsessive compulsive disorder, psychotherapy, cognitive behavioral psychotherapy, exposure and response prevention, children, adolescents

Psychiatry 2007;4(5):47-53 (more…)

Psychiatry 2007;4(5):41-46

by Jonathon Klopp, LCPC; Shane Konrad, MD; Jason Yanofski, MD; and Anita Everett, MD

AUTHOR AFFILIATIONS: Dr. Everett is the section director of the community psychiatry program at Johns Hopkins Bayview; Mr. Klopp is clinical staff at Johns Hopkins, Bayview; and Drs. Konrad and Yanofski are residents in psychiatry at the Johns Hopkins School of Medicine, Department of Psychiatry, Baltimore, Maryland.

Abstract
Identity theft is a serious problem in the United States, and persons with enduring mental illnesses may be particularly vulnerable to becoming victims of this crime. Victims of identity theft experience a variety of consequences that include financial loss and serious emotional distress. Little is known about the impact of identity theft on individuals with mental illnesses. The two cases from a community mental health center presented in this article demonstrate many of the facets that may be associated with an increased risk for becoming the victim of identity theft. A summary of preventive steps as well as steps involved in resolving the crime once one has become a victim are presented.

Key Words: community mental health, identity theft

Psychiatry 2007;4(5):41-46

(more…)

Key Words: social support, health, resilience, stress, cortisol, oxytocin
Psychiatry 2007;4(5):35-40

by FATIH OZBAY, MD; DOUGLAS C. JOHNSON PhD; ELENI DIMOULAS, PhD; C.A. MORGAN III, MD, MA;
DENNIS CHARNEY, MD; and STEVEN SOUTHWICK, MD

AUTHOR AFFILIATIONS: Drs. Ozbay, Johnson, Dimoulas, Morgan, and Southwick are from Yale University School of Medicine, New Haven, Connecticut, and the National Center for PTSD, Clinical Neurosciences Division, VA Medical Center, West Haven, Connecticut; and Dr. Charney is from the Mount Sinai School of Medicine, New York, New York.

Abstract
Numerous studies indicate social support is essential for maintaining physical and psychological health. The harmful consequences of poor social support and the protective effects of good social support in mental illness have been well documented. Social support may moderate genetic and environmental vulnerabilities and confer resilience to stress, possibly via its effects on the hypothalamic-pituitary-adrenocortical (HPA) system, the noradrenergic system, and central oxytocin pathways. There is a substantial need for additional research and development of specific interventions aiming to increase social support for psychiatrically ill and at-risk populations.

(more…)

Psychiatry 2007;4(5):21-23

by Elisa F. Cascade; Amir H. Kalali, MD; Jeffrey Lieberman, MD; John Hsiao, MD; Richard Keefe, PhD; and Scott Stroup, MD

Author Affiliations: Ms. Cascade is Vice President, Strategic Research and Safety, Quintiles Inc., Falls Church, Virginia; Dr. Kalali is Vice President, Global Therapeutic Group Leader CNS, Quintiles Inc., San Diego, California, and Professor of Psychiatry, University of California, San Diego; and Dr. Lieberman is the Lawrence E. Kolb Chairman of Psychiatry at the Columbia University College of Physicians and Surgeons, Director of the New York State Psychiatric Institute, and the Lieber Chair of the Lieber Center for Schizophrenia Research in the Department of Psychiatry at Columbia University, New York, New York; Dr. Hsiao is with the adult treatment and preventive interventions branch of the division of services and interventions research at NIMH in Bethesda, Maryland; Dr. Keefe is Associate Professor of Psychiatry and Behavioral Sciences, Duke University Medical Center, Durham, North Carolina; and Dr. Stroup is Associate Professor of Psychiatry at the University of North Carolina at Chapel Hill and Adjunct Associate Professor of Social Medicine.

Abstract

We investigated the share of branded and generic antipsychotics before and after the publication of the CATIE results in September, 2005. According to our data, the publication of the CATIE results has had very little impact on new patient starts. To determine the impact of CATIE on use of olanzapine (Zyprexa®) subsequent to first line therapy, we also examined product share for switch/add patients. We found that since the publication of the CATIE results, the use of olanzapine has stabilized, following a decline subsequent to first line therapy, and may potentially be growing very slowly. An expert commentary is provided on the data.

Key words: antipsychotic, CATIE, schizophrenia, olanzapine, zyprexa

Psychiatry 2007;4(5):21-23

(more…)